info@uvaxbio.com | CONTACT US

  • About Us
    • The Company
    • The Management
    • The Scientific Advisory Board
  • Technologies
    • The 1c-SApNP Platform Technology
    • Coronavirus Vaccine
    • HIV Vaccine
    • HCV Vaccine
    • RSV/hMPV Vaccines
    • Ebola Vaccine
    • Malaria Vaccine
    • Tuberculosis Vaccine
  • News
  • Publications
  • Investors
  • Our patented 1C-SApNP Platform Technology

    offers a robust pipeline of promising vaccine candidates to address global health challenges
    such as the COVID pandemic, as well as HIV, RSV, HCV, Ebola, Malaria, and Tuberculosis

    LEARN MORE

  • Promising COVID-19 vaccine candidates for evaluation

    Science Advances publishes research article on Uvax-2129,
    Uvax Bio’s patented solution to COVID-19

    Clinical trials to start mid-late 2021

    LEARN MORE

  • New Patent Allowed

    Uvax Bio’s pioneering HCV vaccine design has been allowed by the US Patent Office

Latest News

Cheryl Keech, M.D., Ph.D. has joined Uvax Bio as a Consultant and Acting Chief Medical Officer

November 3, 2021

Uvax Bio LLC, a vaccine biotechnology company based on the single-component self-assembling protein nanoparticle (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA) today announced that Cheryl Keech, MD, Ph.D., has joined the company as… [Read more]

Uvax-2129, a recombinant protein nanoparticle vaccine, Uvax Bio’s answer to COVID-19, shows great promise against variants of concern

November 3, 2021

Uvax-2129, a recombinant protein nanoparticle vaccine, as Uvax Bio’s answer to COVID-19, shows great promise against multiple variants of concern.  Result of a research work funded by the National Institutes of Health and by Uvax Bio LLC published in Science Advances on October 20, 2021… [Read more]

About Uvax Bio

Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.


3801 Kennett Pike
Ste. A101, #4482
Wilmington, DE
19807-9998
info@uvaxbio.com

  • The Company
  • The Management
  • The Scientific Advisory Board
  • News
  • Investors
  • Contact Us
  • The 1c-SApNP Platform Technology
  • Coronavirus Vaccine
  • HIV Vaccine
  • HCV Vaccine
  • RSV/hMPV Vaccines
  • Ebola Vaccine
  • Malaria Vaccine
  • Tuberculosis Vaccine

© Uvax Bio 2022 | Created by TinyFrog Technologies